Skip to content
Screener

Biohaven BHVN Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.18M-33.9%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$57.38M-115%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$43.82M-255%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$64.17M+15.9%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.22M-22.1%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.21B+46.6%
Enterprise value$2.22B+36.2%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Provision for income taxes272609
Net loss$(130,532)$(221,677)
Net loss per share — basic and diluted$(0.88)$(2.17)
Weighted average common shares outstanding—basic and diluted147,615,197101,943,396
Comprehensive loss:
Net loss$(130,532)$(221,677)
Other comprehensive loss, net of tax(46)(6)
Comprehensive loss$(130,578)$(221,683)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's comprehensive income (loss), net of tax, attributable to parent?
Biohaven (BHVN) reported comprehensive income (loss), net of tax, attributable to parent of -$130.58M in Q1 2026.
How has Biohaven's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Biohaven's comprehensive income (loss), net of tax, attributable to parent increased by 41.1% year-over-year, from -$221.68M to -$130.58M.

Ask your AI about Biohaven's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude